Vismodegib como complemento a la cirugía del carcinoma basocelular

• Bernia Petit, E. ^[1] ; Llombart, B. ^[1] ; Serra, C. ^[1] ; Sanmartin Jiménez, O. ^[1]
  1. [1] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
• Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 36, Nº. 2 (FEBRERO), 2021, págs. 121-125
• Idioma: español
• DOI: 10.1016/j.piel.2020.03.011
• Títulos paralelos:
  • Vismodegib: A complement to the basal cell carcinoma surgery
• Enlaces
  • Texto Completo Ejemplar
• Referencias bibliográficas
  • Cirrone F, Harris CS. Vismodegib and the Hedgehog pathway: a new treatment for basal cell carcinoma. CLITHE. 2012;34: 2039–2050.
  • Proctor AE, Thompson LA, Bryant CLO. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma....
  • Ruiz-Salas V, Alegre M, López-Ferrer A, Garcés JR. Vismodegib: revisión. Actas Dermosifiliogr. 2014;105:744–751.
  • Goldenberg G, Karagiannis T, Palmer JB, et al. Incidence and prevalence of basal cell carcinoma (BCC) and locally advanced BCC (LABCC) in...
  • Tejera-Vaquerizo A, Descalzo-Gallego MA, Otero-Rivas MM, et al. Incidencia y mortalidad del cáncer cutáneo en España: revisión sistemática...
  • McCusker M, Basset-Seguin N, Dummer R, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease....
  • Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171–2179.
  • Basset-Séguin N, Hauschild A, Kunstfeld R, et al. Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STEVIE, an...
  • Dréno B, Kunstfeld R, Hauschild A, et al. Two intermittent vismodegib dosing regimens in patients with multiple basalcell carcinomas (MIKIE):...
  • Scalvenzi M, Villani A, Costa C, Cappello M. Efficacy and safety of vismodegib in patients with basal cell carcinoma: an Italian center experience....
  • Bernia E, Llombart B, Serra-Guillén C, et al. Experiencia con vismodegib en carcinoma basocelular avanzado en un centro oncológico. Actas...
  • Mortier L, Bertrand N, Basset-Seguin N, et al. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: first results...
  • Ally MS, Aasi S, Wysong A, et al. An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk...
  • Herms F, Haudebourg L, Bagot M, et al. Follow-up of patients with complete remission of locally advanced basal cell carcinoma treated with...
  • Woltsche N, Pichler N, Wolf I, Di Meo N, Zalaudek I. Managing adverse effects by dose reduction during routine treatment of locally advanced...
  • Mohan SV, Chang J, Li S, Henry AS, Wood DJ, Chang ALS. Increased risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal...
  • Puig S, Sampogna F, Tejera-Vaquerizo A. Study on the risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma....
  • Li S, Chang ALS. Study on the risk of cutaneous squamous cell carcinoma after vismodegib therapy for basal cell carcinoma —reply. JAMA Dermatol....
  • Bhutani T, Abrouk M, Sima CS, et al. Risk of cutaneous squamous cell carcinoma after treatment of basal cell carcinoma with vismodegib. J...
  • Bancalari B, Llombart B, Serra-Guillén C, et al. Histologic changes during treatment with vismodegib in locally advanced basal cell carcinoma....